Also Read | Dissecting Ola’s audacious electric dreamsThe announcement is significant for India in its fight against covid-19 pandemic, where the world’s largest vaccine manufacturer, Serum Institute of India, will be manufacturing 1 billion doses of the shot under its brand Covovax.The data was from its UK trials, where it has enrolled more than 15,000 participants, including 27% over the age of 65.The vaccine was 86.3% effective against the mutant variant discovered in the UK.
The overall efficacy across its UK trial was 89.7%, similar to the 89.3% interim efficacy the company had reported in January.In the UK trial, 106 participants were confirmed to have contracted covid-19, with only 10 in the vaccine group and the rest in the placebo.